

GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India. Voice: +91-40-2784 9700 / 2784 2602 / 2784 4557

E-mail: info@godavaridrugs.com | Website: www.godavaridrugs.com

14.11.2023

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Submission of Un-Audited Financial Results of the Company and Limited Review Report as per the provisions of Regulation 33 of SEBI (LODR) Regulations, 2015

Please find the enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

- 1. Un-audited Financial Results of the Company for the quarter and half year ended 30th September, 2023.
- 2. A certified copy of Limited Review Report on standalone financials for the quarter and half year ended 30th September, 2023 given by the statutory auditors.

These are also being made available on the website of the Company at www.godavaridrugs.com.

The Board Meeting Commenced at 03:45 P.M and concluded at 04:40 PM

Please take the above in your records.

Thanking You, For Godavari Drugs Limited

Venkatesh Achanta Company Secretary & Compliance Officer

Plant: A-6/2, MIDC, Nanded - 431 603. MS, India. E-mail: nnd@godavaridrugs.comCIN:L24230TG1987PLC008016

GODAVARI DRUGS LIMITED

CIN NO.L24230TG1987PLC008016

Regd. Office: - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

(Rs. In Lakhs)

| 0. | Particulars | Quarter ended | | | Half Year Ended | | Year ended | |
|------------|---|---------------|-------------|-------------|-----------------|-------------|------------|--|
| SI. No. | | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | 31.03.2023 | |
| 140. | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | |
| 1 | Revenue from operations | 3954.25 | 3541.88 | 4054.71 | 7496.13 | 8309.71 | 15962.48 | |
| 2 | Other Income | 0.35 | 45.21 | 13.20 | 45.56 | 19.88 | 65.53 | |
| 3 | Total Revenue from operations (1+2) | 3954.60 | 3587.09 | 4067.91 | 7541.69 | 8329.59 | 16028.01 | |
| 4 | Expenses | | | | | | | |
| | (a) Cost of materials consumed | 3035.42 | 2644.34 | 3662.06 | 5679.76 | 7551.69 | 13782.07 | |
| | (b) Changes in inventories of finished goods & work-in-progress | 40.27 | 162.33 | -371.12 | 202.60 | -838.24 | -976.30 | |
| | (c) Employee benefits expense | 119.06 | 121.95 | 113.93 | 241.01 | 230.71 | 484.04 | |
| | (d) Depreciation & amortization expense | 49.38 | 47.38 | 47.25 | 96.76 | 93.35 | 194.35 | |
| | (e) Finance Costs | 129.81 | 110.98 | 105.69 | 240.79 | 179.87 | 392.73 | |
| | (f) Other Expenses | 453.23 | 388.39 | 393.06 | 841.62 | 868.62 | 1680.59 | |
| | Total expenses | 3827.17 | 3475.37 | 3950.89 | 7302.54 | 8086.00 | 15557.48 | |
| 5 | Profit before exceptional Items and tax (3-4) | 127.43 | 111.72 | 117.02 | 239.15 | 243.59 | 470.53 | |
| 6 | Exceptional items | | | | | | 22.95 | |
| 7 | Profit before Tax (5-6) | 127.43 | 111.72 | 117.02 | 239.15 | 243.59 | 493.48 | |
| 8 | Tax expense | (41.85) | (30.68) | (30.63) | (72.53) | (65.03) | (114.89) | |
| 9 | Net Profit for the period (7-8) | 85.58 | 81.04 | 86.39 | 166.62 | 178.56 | 378.58 | |
| 10 | Other Comprehensive Income | | | | | | | |
| | Items that will not be reclassified to profit or (i) loss | | | 1- | | | | |
| | Income tax relating to Items that will not be (ii) reclassified to profit or loss | | | | | | | |
| | Items that will be reclassified to profit or (iii) loss | | | | | | | |
| | Income tax relating to Items that will be (iv) reclassified to profit or loss | | | | | | | |
| 11 | Total Comprehensive Income (9+10) | 85.58 | 81.04 | 86.39 | 166.62 | 178.56 | 378.58 | |
| 12 | Paid-up equity share capital (Face Value Rs. 10/- per share) | 753.05 | 753.05 | 753.05 | 753.05 | 753.05 | 753.05 | |
| 13 | Other Equity(Reserves and Surplus) | | | | | | 2588.67 | |
| 14 | Earnings per share (of Rs.10/- each) (not annualized) | | | | | | | |
| | (a) Basic | 1.14 | 1.08 | 1.15 | 2.21 | 2.37 | 5.03 | |
| | (b) Diluted | 1.14 | 1.08 | 1.15 | 2.21 | 2.37 | 5.03 | |

Notes:

- 1. The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 14thNovember2023
- 2. The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- 3. The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.

4. Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

SEC'BAL

Whole Time Director/CFO

DIN: 03405414

Place: Secunderabad Date:

14-11-2023

Godavari Drugs Limited Cash Flow Statement for the half year ended September 30,2023

(Rs. In Lakhs)

| Particulars | | Period ended 30.09.2023 | Previous Year 2022-23 |
|---|---------|----------------------------|--------------------------|
| A. Cash Flow from Operating Activities | | | |
| Profit before Depreciation, Interest and Tax | | 576.70 | 1080.55 |
| Other income considered separately | | -45.55 | -65.53 |
| | Net | 531.14 | 1015.02 |
| (Increase) / Decrease in Inventories | | 137.56 | -982.19 |
| (Increase) / Decrease in Receivables | | -574.70 | |
| (Increase) / Decrease in Short term Loans & Advances | | 0.06 | |
| (Increase) / Decrease in Other Current Assets | | 224.19 | |
| Increase / (Decrease) in Current Liabilities | | 449.93 | 1607.91 |
| Less: Income tax paid | | -66.77 | -101.67 |
| Less: Deferred Tax Adjustment | | -5.75 | -13.22 |
| | Total A | 695.66 | 1321.71 |
| B. Cash Flow from Investing Activities | | | |
| Increase in Fixed Assets and Capital WIP (net) | | -429.91 | -929.67 |
| Increase in Non Current Assets | | -86.64 | -10.61 |
| Other Income | | 45.56 | 61.60 |
| Sale of retired fixed assets (Scrap) | | 0.00 | 14.83 |
| C Cash Flow from Financing Activities | Total B | -471.00 | -863.85 |
| C. Cash Flow from Financing Activities | | | |
| Increase / (Decrease) in Long Term Borrowings | | -41.75 | 16.54 |
| Increase / (Decrease) in Long Term Provisions | | -1.26 | -0.84 |
| Increase / (Decrease) in Long Term Advances | | 0.00 | 0.00 |
| Interest Paid | | -240.79 | -392.73 |
| | Total C | -283.79 | -377.03 |
| D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C] | | -59.13 | 80.83 |
| Cash and cash equivalents at the beginning of the year (01.04.2023) | | 308.46 | 227.64 |
| Cash and cash equivalents at the end of the year (30.09.2023) | | 249.33 | 308.46 |
| Increase/(-)Decrease | | -59.13 | 80.83 |

For GODAVARI DRUGS LIMITED

Mohit Jaju

Whole Time Director/CFO

DIN: 03405414

Place: Secunderabad Date: 14.11.2023



GODAVARI DRUGS LIMITED

CIN NO.L24230TG1987PLC008016

Regd. Office: - "Mayfair", S.P.Road, Secunderabad.

Statement of Assets and Liabilities

Place: Secunderabad Date: 14.11.2023

| Particulars | Half Year ended (30.09.2023) | (Rs. In Lakhs) Year ended (31.03.2023) | |
|---|---------------------------------|--|--|
| ASSETS | (Unaudited) | (Audited) | |
| Non - current assets | | | |
| a. Property, plant and equipment | 2396.17 | 2491.00 | |
| b. Capital work - in -progress | 1335.51 | 907.53 | |
| c. Investment Property | 1333.31 | 907.5 | |
| d. Goodwill | | | |
| e. Other Intangible assets | | | |
| f. Intangible assets under development | | | |
| g. Biological Assets other than bearer plants | | | |
| h. Financial Assets | | | |
| (i) Investments | 0.01 | 0.0 | |
| (ii) Trade Receivables | 0.01 | 0.03 | |
| (iii) Loans | | | |
| (iv) Other Financial Assets | 120.02 | | |
| i. Deferred tax assets (net) | 130.82 | 44.18 | |
| i. Other non-current assets | | | |
| | | | |
| 2. Current assets | 1010.01 | | |
| (a) Inventories | 1848.01 | 1985.57 | |
| (b) Financial Assets | | | |
| (i) Investments | | | |
| (ii) Trade Receivables | 6368.20 | 5793.49 | |
| (iii) Cash and cash equivalents | 249.33 | 308.46 | |
| (iv) Bank balances other than (iii) above | | | |
| (v) Loans | 88.69 | 88.75 | |
| (vi) Others (to be specified) | | | |
| (c) Current Tax Assets (Net) | | | |
| (d) Other current assets | 300.11 | 524.30 | |
| | | | |
| Total Assets | 12716.84 | 12143.30 | |
| EQUITY AND LIABILITIES | | | |
| EQUITY | | | |
| (a) Equity Share capital | 753.05 | 753.05 | |
| (b) Other Equity | 2755.29 | 2588.67 | |
| (i) Reserves and surplus | | | |
| Non controlling interest | | | |
| LIABILITIES | | | |
| 1. Non - current liabilities | | | |
| (a) Financial Liabilities | | | |
| (i) Borrowings | 1153.00 | 1194.75 | |
| (ii) Trade payables | | | |
| (iii) Other financial liabilities (other than | | | |
| those specified in item (b) | | | |
| (b) Provisions | 70.18 | 71.43 | |
| (c) Deferred tax liabilities (Net) | 170.34 | 164.58 | |
| (d) Other non-current liabilities | | 20.100 | |
| 2. Current liabilities | | | |
| (a) Financial Liabilities | | | |
| (i) Borrowings | 2217.42 | 2154.88 | |
| (ii) Trade payables | 2217.42 | 2134.00 | |
| (A) Total outstanding dues of micro | | | |
| enterprise and small enterprise and | | 11.00 | |
| · | - | 11.99 | |
| (B) Total outstanding dues creditors | | | |
| other than of micro enterprise and | 1000.05 | | |
| small enterprise | 4930.95 | 4602.87 | |
| (iii) Other financial liabilities (other than | 599.84 | 499.41 | |
| those specified in item (c) | | | |
| (b) Other current liabilities | | | |
| (c) Provisions | | | |
| (d) Current Tax Liabilities (Net) | 66.77 | 101.67 | |
| | | | |
| | | | |

GODAVARI DRUGS LIMITED

Monit laju Whole Time Director/CFO DIN: 03405414



Ayyadevara & Co.

Chartered Accountants

1-2-386/A/1, Gagan Mahal Hyderabad - 500 029 Ph. +91-40-27632354, 27642952

e-mail sndevar@yahoo.co.in URL www.ayyadevara.com

Independent Auditor's Review Report on unaudited quarterly financial results of Godavari Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Board of Directors Godavari Drugs Limited Hyderabad

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and half year ended on September, 30, 2023 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

CHARTERED

For Ayyadevara & Co., Chartered Accountants

FRN: 00278S

Ayyadevara Srinivas

Proprietor

ICAI Membership No. 028803 Hyderabad, Nov 14, 2023.

UDIN: 23028803BGZHKQ1694